Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients withFGF9upregulation may be resistant to anti-EGFR therapies-Reference-Cited by-同舟云学术

Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients withFGF9upregulation may be resistant to anti-EGFR therapies

Published:2016-02-24 Issue:1 Volume:56 Page:106-117
ISSN:0899-1987
Container-title:Molecular Carcinogenesis
language:en
Short-container-title:Mol. Carcinog.

Author:

Mizukami Takuro¹²,Togashi Yosuke¹,Naruki Saeko³,Banno Eri¹,Terashima Masato¹,de Velasco Marco A.¹,Sakai Kazuko¹,Yoneshige Azusa⁴,Hayashi Hidetoshi¹⁵,Fujita Yoshihiko¹,Tomida Shuta¹,Nakajima Takako Eguchi²,Fujino Takashi³,Boku Narikazu²,Ito Akihiko⁴,Nakagawa Kazuhiko⁵,Nishio Kazuto¹

Affiliation:

1. Department of Genome Biology; Kinki University School of Medicine; Osaka-Sayama Osaka Japan

2. Department of Clinical Oncology; St. Marianna University School of Medicine; Kawasaki Kanagawa Japan

3. Department of Pathology; St. Marianna University School of Medicine; Kawasaki Kanagawa Japan

4. Department of Pathology; Kinki University School of Medicine; Osaka-Sayama Osaka Japan

5. Department of Medical Oncology; Kinki University School of Medicine; Osaka-Sayama Osaka Japan

Funder

Applied Research for Innovative Treatment of Cancer Program

Japan Agency for Medical Research and Development (AMED) established by the Ministry of Health, Labour

Welfare of Japan and Grant-in-Aid for Research Activity start-up

Publisher

Wiley

Subject

Cancer Research,Molecular Biology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/mc.22476/fullpdf

Reference42 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer;Van Cutsem;N Engl J Med,2009

3. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer;Bokemeyer;J Clin Oncol,2009

4. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials;Bokemeyer;Eur J Cancer,2012

5. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer;Vaughn;Genes Chromosomes Cancer,2011

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel six-gene prognostic signature based on colon adenocarcinoma immune-related genes;BMC Bioinformatics;2022-10-11

2. Advanced Peptide Nanomedicines for Bladder Cancer Theranostics;Frontiers in Chemistry;2022-08-05

3. The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy;Frontiers in Molecular Biosciences;2022-03-30

4. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models;Genome Medicine;2021-07-16

5. Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer;Cancer Research;2021-06-03